Skip to main
JANX
JANX logo

Janux Therapeutics (JANX) Stock Forecast & Price Target

Janux Therapeutics (JANX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Janux Therapeutics Inc is leveraging its proprietary platforms, TRACTr and TRACIr, to develop innovative tumor-activated immunotherapies, which may significantly enhance the efficacy of treatments in patients with low target expression. The company anticipates a strong growth trajectory through 2024, particularly within the VISION population, suggesting a promising market expansion opportunity. Additionally, potential improvements in drug activity could facilitate the positioning of JANX007 in earlier treatment lines, thereby increasing patient outcomes and investment appeal through enhanced durability.

Bears say

Janux Therapeutics Inc. exhibits a concerning outlook due to inconsistent efficacy results from its clinical trials, particularly highlighted by the significant drop in the Kaplan-Meier (KM) curve at the time of first scan, suggesting that its leading candidate, pasritamig, may not be suitable for all patient populations. Additionally, while some VISION trial patients showed promising median radiographic progression-free survival (rPFS) benefits, the overall data indicates that these outcomes are not representative across the broader patient group treated with Pluvicto. Such variability raises questions about the reliability of Janux's therapeutic approach and could hinder investor confidence in the company's future performance in the competitive biopharmaceutical market.

Janux Therapeutics (JANX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Janux Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Janux Therapeutics (JANX) Forecast

Analysts have given Janux Therapeutics (JANX) a Buy based on their latest research and market trends.

According to 11 analysts, Janux Therapeutics (JANX) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $76.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $76.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Janux Therapeutics (JANX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.